GDF15 promotes weight loss by enhancing energy expenditure in muscle
Dongdong Wang,Logan K Townsend,Geneviève J DesOrmeaux,Sara M Frangos,Battsetseg Batchuluun,Lauralyne Dumont,Rune Ehrenreich Kuhre,Elham Ahmadi,Sumei Hu,Irena A Rebalka,Jaya Gautam,Maria Joy Therese Jabile,Chantal A Pileggi,Sonia Rehal,Eric M Desjardins,Evangelia E Tsakiridis,James S V Lally,Emma Sara Juracic,A Russell Tupling,Hertzel C Gerstein,Guillaume Paré,Theodoros Tsakiridis,Mary-Ellen Harper,Thomas J Hawke,John R Speakman,Denis P Blondin,Graham P Holloway,Sebastian Beck Jørgensen,Gregory R Steinberg
DOI: https://doi.org/10.1038/s41586-023-06249-4
IF: 64.8
Nature
Abstract:Caloric restriction that promotes weight loss is an effective strategy for treating non-alcoholic fatty liver disease and improving insulin sensitivity in people with type 2 diabetes1. Despite its effectiveness, in most individuals, weight loss is usually not maintained partly due to physiological adaptations that suppress energy expenditure, a process known as adaptive thermogenesis, the mechanistic underpinnings of which are unclear2,3. Treatment of rodents fed a high-fat diet with recombinant growth differentiating factor 15 (GDF15) reduces obesity and improves glycaemic control through glial-cell-derived neurotrophic factor family receptor α-like (GFRAL)-dependent suppression of food intake4-7. Here we find that, in addition to suppressing appetite, GDF15 counteracts compensatory reductions in energy expenditure, eliciting greater weight loss and reductions in non-alcoholic fatty liver disease (NAFLD) compared to caloric restriction alone. This effect of GDF15 to maintain energy expenditure during calorie restriction requires a GFRAL-β-adrenergic-dependent signalling axis that increases fatty acid oxidation and calcium futile cycling in the skeletal muscle of mice. These data indicate that therapeutic targeting of the GDF15-GFRAL pathway may be useful for maintaining energy expenditure in skeletal muscle during caloric restriction.